用于非酒精性脂肪性肝病药物治疗的抗糖尿病药物
Anti-Diabetic Medications for the Pharmacologic Management of NAFLD.
作者信息
Cholankeril Rosann, Patel Vikram, Perumpail Brandon J, Yoo Eric R, Iqbal Umair, Sallam Sandy, Shah Neha D, Kwong Waiyee, Kim Donghee, Ahmed Aijaz
机构信息
Department of Medicine, Roger Williams Medical Center, Providence, RI 02908, USA.
Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA.
出版信息
Diseases. 2018 Oct 3;6(4):93. doi: 10.3390/diseases6040093.
Abstract
As a chronic disease encompassing a wide spectrum of liver-related histologic damage, nonalcoholic fatty liver disease (NAFLD) is becoming a global epidemic with significant impacts on all-cause morbidity and mortality. Insulin resistance and type 2 diabetes mellitus predispose individuals to NAFLD and related complications. Therefore, timely intervention with anti-diabetic medications may prevent and delay the development of NAFLD or have a therapeutic implication. The focus of this review is to evaluate the evidence supporting the efficacy of anti-diabetic medications in the treatment of NAFLD. While many of these anti-diabetic agents have shown to improve biochemical parameters, their effect on hepatic histology is limited. Among anti-diabetic medications, only thiazolidinediones and glucagon-like peptide-1 receptor agonists demonstrate significant improvement in hepatic histology.
摘要
非酒精性脂肪性肝病（NAFLD）作为一种涵盖广泛肝脏相关组织学损伤的慢性疾病，正成为一种全球性流行病，对全因发病率和死亡率产生重大影响。胰岛素抵抗和2型糖尿病使个体易患NAFLD及相关并发症。因此，及时使用抗糖尿病药物进行干预可能预防和延缓NAFLD的发展或具有治疗意义。本综述的重点是评估支持抗糖尿病药物治疗NAFLD疗效的证据。虽然这些抗糖尿病药物中的许多已显示可改善生化指标，但其对肝脏组织学的影响有限。在抗糖尿病药物中，只有噻唑烷二酮类和胰高血糖素样肽-1受体激动剂可使肝脏组织学有显著改善。
相似文献
1
Anti-Diabetic Medications for the Pharmacologic Management of NAFLD.用于非酒精性脂肪性肝病药物治疗的抗糖尿病药物
Diseases. 2018 Oct 3;6(4):93. doi: 10.3390/diseases6040093.
2
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!新型抗糖尿病药物对非酒精性脂肪肝和脂肪性肝炎的影响：另辟蹊径！
Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28.
3
Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.比较 2 型糖尿病患者抗糖尿病药物对非酒精性脂肪性肝病的疗效：随机和非随机研究的系统评价和荟萃分析。
Diabetes Metab Res Rev. 2016 Feb;32(2):200-16. doi: 10.1002/dmrr.2713. Epub 2015 Nov 1.
4
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.治疗糖尿病药物在非酒精性脂肪性肝病治疗中的作用。
Curr Diab Rep. 2020 Oct 5;20(11):59. doi: 10.1007/s11892-020-01349-1.
5
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.非酒精性脂肪性肝病伴或不伴糖尿病患者的降糖药物疗效和安全性：一项更新的随机对照试验系统评价。
Diabetes Metab. 2020 Nov;46(6):427-441. doi: 10.1016/j.diabet.2019.12.007. Epub 2020 Jan 7.
6
Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety.2型糖尿病患者非酒精性脂肪性肝病的治疗：疗效与安全性综述
Ther Adv Endocrinol Metab. 2018 Jan;9(1):15-28. doi: 10.1177/2042018817741852. Epub 2017 Dec 7.
7
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis.比较胰高血糖素样肽-1 受体激动剂和噻唑烷二酮类药物治疗非酒精性脂肪性肝病的疗效：一项网状荟萃分析。
Clin Mol Hepatol. 2023 Jul;29(3):693-704. doi: 10.3350/cmh.2022.0330. Epub 2023 Mar 9.
8
Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.非酒精性脂肪性肝病和脂肪性肝炎的管理
J Clin Exp Hepatol. 2012 Jun;2(2):156-73. doi: 10.1016/S0973-6883(12)60104-2. Epub 2012 Jul 21.
9
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.2型糖尿病合并非酒精性脂肪性肝病患者的治疗：当前方法与未来方向
Diabetologia. 2016 Jun;59(6):1112-20. doi: 10.1007/s00125-016-3952-1. Epub 2016 Apr 21.
10
Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.用于治疗2型糖尿病合并非酒精性脂肪性肝病的新型抗糖尿病药物。
Hepatol Res. 2017 Mar;47(4):266-280. doi: 10.1111/hepr.12856. Epub 2017 Feb 13.
引用本文的文献
1
Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis.非酒精性脂肪性肝炎药物治疗后肝纤维化的消退
World J Gastrointest Pharmacol Ther. 2024 Nov 5;15(6):97381. doi: 10.4292/wjgpt.v15.i6.97381.
2
Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review.代谢功能障碍相关脂肪性肝病引起的抗氧化系统变化：综述
Arch Toxicol. 2025 Jan;99(1):1-22. doi: 10.1007/s00204-024-03889-x. Epub 2024 Oct 23.
3
Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.非酒精性脂肪性肝病与肥胖症：肥胖医学协会（OMA）2022年临床实践声明（CPS）
Obes Pillars. 2022 Jul 8;3:100027. doi: 10.1016/j.obpill.2022.100027. eCollection 2022 Sep.
4
Hunger & satiety signals: another key mechanism involved in the NAFLD pathway.饥饿和饱腹感信号：参与 NAFLD 途径的另一个关键机制。
Front Endocrinol (Lausanne). 2023 Sep 11;14:1213372. doi: 10.3389/fendo.2023.1213372. eCollection 2023.
5
Advances in Unhealthy Nutrition and Circadian Dysregulation in Pathophysiology of NAFLD.非酒精性脂肪性肝病病理生理学中不健康营养与昼夜节律失调的进展
Front Clin Diabetes Healthc. 2021 Oct 12;2:691828. doi: 10.3389/fcdhc.2021.691828. eCollection 2021.
6
Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation.验证一种用于非酒精性脂肪性肝病（NAFLD）临床前治疗效果评估的脂肪-肝脏人源化芯片模型。
Sci Rep. 2021 Jun 23;11(1):13159. doi: 10.1038/s41598-021-92264-2.
7
Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.非酒精性脂肪性肝病中的肝纤维化：从肝活检到诊断和治疗中的非侵入性生物标志物
Front Med (Lausanne). 2021 Apr 14;8:615978. doi: 10.3389/fmed.2021.615978. eCollection 2021.
8
Combination of bis (α-furancarboxylato) oxovanadium (IV) and metformin improves hepatic steatosis through down-regulating inflammatory pathways in high-fat diet-induced obese C57BL/6J mice.双（α-呋喃甲酰基）氧钒（IV）和二甲双胍的联合作用通过下调高脂肪饮食诱导肥胖 C57BL/6J 小鼠的炎症通路改善肝脂肪变性。
Basic Clin Pharmacol Toxicol. 2021 Jun;128(6):747-757. doi: 10.1111/bcpt.13573. Epub 2021 Mar 14.
9
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease.非酒精性脂肪性肝病肝外表现的评估与管理。
Clin Mol Hepatol. 2021 Apr;27(2):221-235. doi: 10.3350/cmh.2020.0239. Epub 2020 Dec 3.
10
S-allylmercaptocysteine improves nonalcoholic steatohepatitis by enhancing AHR/NRF2-mediated drug metabolising enzymes and reducing NF-κB/IκBα and NLRP3/6-mediated inflammation.S-烯丙基半胱氨酸通过增强 AHR/NRF2 介导的药物代谢酶和减少 NF-κB/IκBα 和 NLRP3/6 介导的炎症来改善非酒精性脂肪性肝炎。
Eur J Nutr. 2021 Mar;60(2):961-973. doi: 10.1007/s00394-020-02305-1. Epub 2020 Jun 17.
本文引用的文献
1
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).抗糖尿病药物对非酒精性脂肪性肝病（NAFLD）的影响。
Hormones (Athens). 2018 Jun;17(2):219-229. doi: 10.1007/s42000-018-0021-9. Epub 2018 Apr 17.
2
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis.非酒精性脂肪性肝病与 2 型糖尿病发病风险：荟萃分析。
Diabetes Care. 2018 Feb;41(2):372-382. doi: 10.2337/dc17-1902.
3
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.噻唑烷二酮类药物与非酒精性脂肪性肝炎中的晚期肝纤维化：一项荟萃分析。
JAMA Intern Med. 2017 May 1;177(5):633-640. doi: 10.1001/jamainternmed.2016.9607.
4
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.西他列汀用于非酒精性脂肪性肝炎患者：一项随机、安慰剂对照试验。
World J Gastroenterol. 2017 Jan 7;23(1):141-150. doi: 10.3748/wjg.v23.i1.141.
5
Therapies in non-alcoholic steatohepatitis (NASH).非酒精性脂肪性肝炎（NASH）的治疗方法。
Liver Int. 2017 Jan;37 Suppl 1(Suppl 1):97-103. doi: 10.1111/liv.13302.
6
Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.依帕列净治疗2型糖尿病患者可改善脂肪肝指数：与降糖效果相关
Endocr J. 2017 Mar 31;64(3):363-367. doi: 10.1507/endocrj.EJ16-0295. Epub 2016 Dec 13.
7
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂对日本非酒精性脂肪性肝病合并2型糖尿病患者肝功能检查的影响。
Hepatol Res. 2017 Sep;47(10):1072-1078. doi: 10.1111/hepr.12834. Epub 2016 Dec 7.
8
Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.12周度拉糖肽治疗对经活检证实的日本非酒精性脂肪性肝病合并2型糖尿病患者的疗效。
Hepatol Res. 2017 Oct;47(11):1206-1211. doi: 10.1111/hepr.12837. Epub 2016 Dec 5.
9
The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background.非酒精性脂肪性肝病的发病机制：饮食、肠道微生物群与遗传背景之间的相互作用
Gastroenterol Res Pract. 2016;2016:2862173. doi: 10.1155/2016/2862173. Epub 2016 May 9.
10
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.西他列汀与安慰剂治疗非酒精性脂肪性肝病的随机对照试验。
J Hepatol. 2016 Aug;65(2):369-76. doi: 10.1016/j.jhep.2016.04.021. Epub 2016 May 2.
Zotero 插件